AC Immune SA

From Verify.Wiki
Jump to: navigation, search
AC Immune SA
Type Public
Industry Biotechnology
Founded 2003
Headquarters Lausanne, Switzerland
Key people Andrea Pfeifer (Co-Founder & CEO), Jean-Fabien Monin (CFO), Andreas Muhs (CSO) [1]
Investors Dietmar Hopp
Number of employees 62 [2]

AC Immune SA, a clinical stage Swiss-based biopharmaceutical company, focuses on neurodegenerative diseases with three product candidates in clinical trials. It designs, discovers, and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. The company’s technology platforms create antibodies, small molecules, and vaccines to address a broad spectrum of neurodegenerative indications. It offers its therapies to address Alzheimer disease and neurodegenerative diseases, such as Parkinson’s, Down syndrome, and glaucoma.
AC Immune SA was founded in 2003 and is based in Lausanne, Switzerland. [3]



Top 5 Recent Tweets

March 18, 2018AlzheimersLinkAC Immune SA (ACIU) Given $26.00 Average Price Target by Analysts #Alzheimers #mentalhealth
March 17, 2018AlzheimersLinkAC Immune SA (NASDAQ:ACIU) Shares Bought by Tekla Capital Management LLC #Alzheimers #mentalhealth
March 17, 2018AlzheimersLinkAC Immune (NASDAQ:ACIU) Lifted to Hold at BidaskClub #Alzheimers #mentalhealth
March 17, 2018OlympiaReportAC Immune SA $ACIU Receives Average Rating of “Strong Buy” from Brokerages
March 17, 2018ThisLincolnianAC Immune SA $ACIU Given $26.00 Average Price Target by Analysts

Top 5 Recent News Headlines

Top 5 Lifetime Tweets

Top 5 Lifetime News Headlines


Verification history